Anales de la RANM

139 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 MELATONINA Y COVID-19 Fernández Tresguerres JA, et al. An RANM. 2022;139(02): 135 - 139 latonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583. https://doi. org/10.1016/j.lfs.2020.117583 28. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS co- ronavirus S protein efficiently binds angioten- sin-converting enzyme 2. J Biol Chem. 2004; 279(5): 3197-3201. 29. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS- CoV- 2 by full-length human ACE2. Science. 2020; 367(6485): 1444-1448. 30. Gurwitz, D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 81: 537-540. 31. Benítez-King G, Ríos A, Martínez A, Antón- Tay F. In vitro inhibition of Ca2+/calmodulin dependent kinase II activity by melatonin. Bio- chim Biophys Acta Gen Subj. 1996; 1290(2): 191-196. 32. Benítez-King G, Huerto-Delgadillo L, Antón- Tay F. Binding of 3H-melatonin to calmodu- lin. Life Sci. 1993; 53: 201-207. 33. Romero MP, García-Perganeda A, Guerrero JM, Osuna C. Membrane bound calmodulin in Xenopus Laevis oocites as a novel binding domain for melatonin. FASEB J. 1998;12(13): 1401-1408. https://faseb.onlinelibrary.wiley. com/doi/full/10.1096/fasebj.12.13.1401 34. Lambert DW , Clarke NE, Hooper NM, Turner AJ. Calmodulin interacts with angiotensin converting enzyme 2 (ACE2) and inhibits the shedding of its ectodomain. FEBS L ett. 2008; 582(2): 385-390. 35. Klann K, Bojkova D, Tascher G, Ciesek S, Münch C, Cinatl J. Growth factor receptor sig- naling inhibition prevents SARS-CoV-2 repli- cation. Moll Cell. 2020; 80(1):164-174.e4. doi: 10.1016/j.molcel.2020.08.006. 36. Tesarik J. Melatonin attenuates GRF signaling required for SARS-CoV-2 replication. Melato- nin Res. 2020; 3(4): 534-537. 37. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan D-X, Reiter RJ. Beneficial actions of me- latonin in the management of viral infections: a new use for this “molecular handyman”? Rev Med Virol. 2012; 22(5): 323-338. 38. Anderson G, Maes M, Markus RP, Rodriguez M. Ebola virus: Melatonin as a readily availa- ble treatment option. J Med Virol. 2015; 87(4): 537-543. https://doi.org/10.1002/jmv.24130 39. Ben-Nathan D, Maestroni GJ, Lustig S, Con- ti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol. 1995; 140(2): 223-230. https://doi. org/10.1007/bf01309858 40. García-García I, Seco-Meseguer E, Ruiz- Seco P et al. Melatonin in the prophilaxis of SARS-CoV-2 infection in healthcare workers: a randomized clinical trial. J Clin Med. 2022; 11(4): 1139. doi: 10.3390/jcm11041139 41. Bagheri M, Izadi M, Saeedi-Boroujeni A et al. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID 19: a randomized double blind clinical trial. Arch Medical Research. 2022; 53: 79-85. DECLARACIÓN DE TRANSPARENCIA Los autores/as de este artículo declaran no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. Si desea citar nuestro artículo: Fernández-Tresguerres JA, Rancan L, Paredes S, Vara E, Sán- chez García M. Melatonina: bases científicas para su uso en el Covid 19. An RANM. 2022;139(02): 135– 139. DOI: 10.32440/ ar.2022.139.02. rev03